IngentaConnect Prevalence of primary and acquired resistance of Mycobacterium tu...

Authors: A. Trébucq¹; S. Anagonou²; M. Gninafon²; K. Lambregts³; F. Boulahbal⁴

Source: The International Journal of Tuberculosis and Lung Disease, Volume 3, Number 6, June 1999 , pp. 466-470(5)

Publisher: International Union Against Tuberculosis and Lung Disease

Abstract:

SETTING: Benin National Tuberculosis Programme, West Africa.

OBJECTIVE: To measure the prevalence of primary and acquired resistance of Mycobacterium tuberculosis to the antituberculosis drugs isoniazid, rifampicin, ethambutol and streptomycin in Benin from 1994–1995, after 12 years of short-course chemotherapy regimens.

METHODS: Prospective study by cluster sampling according to the methodology recommended by the International Union Against Tuberculosis and Lung Disease (IUATLD) and the World Health Organization (WHO).

RESULTS: The survey of primary resistance included 333 strains, of which 28 (8.4%) were drug-resistant, one to both rifampicin and isoniazid (multidrug-resistant). For acquired resistance, out of 57 strains tested 26 (45.6%) were resistant, six of which (11%) were multidrug-resistant.

CONCLUSION: Despite the considerable increase in the number of tuberculosis cases observed in recent years (52% between 1987 and 1995), direct observation of patients taking their antituberculosis drugs during the intensive phase of treatment has limited the development of drug resistance in Benin.

Keywords: drug resistance; tuberculosis; Benin; Africa

Document Type: Regular paper

Affiliations: 1: International Union Against Tuberculosis and Lung Disease (IUATLD), Paris, France 2: National Tuberculosis Programme, Cotonou, Benin 3: Royal Netherlands Tuberculosis Association (KNCV), Gravenhage, The Netherlands 4: Institut Pasteur, Centre National de Référence des Mycobactéries, Paris, France

Prevalence of primary and acquired resistance of Mycobacterium tuberculosis to antituberculosis drugs in Benin after 12 years of short-course chemotherapy